Lisata Therapeutics (LSTA) director reports 30,456 RSUs grant award

Rhea-AI Filing Summary

Lisata Therapeutics director Gregory B. Brown reported receiving 30,456 restricted stock units of common stock on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan. These restricted stock units are scheduled to vest on January 9, 2027. Following this grant, he beneficially owns 95,659 shares of Lisata Therapeutics common stock, including 30,456 unvested restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BROWN GREGORY B

(Last) (First) (Middle)

C/O LISATA THERAPEUTICS, INC.

110 ALLEN ROAD, 2ND FLOOR

(Street)

BASKING RIDGE NJ 07920

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		30,456(1)	A	$0	95,659(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.

2. Includes 30,456 unvested restricted stock units.

Remarks:

	James Nisco, Attorney-in-Fact for Gregory B. Brown	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for LSTA by Gregory B. Brown?

Director Gregory B. Brown reported an award of 30,456 restricted stock units of Lisata Therapeutics common stock, granted on January 9, 2026.

When do Gregory B. Brown’s new Lisata Therapeutics restricted stock units vest?

The 30,456 restricted stock units granted to Gregory B. Brown are scheduled to vest on January 9, 2027.

How many Lisata Therapeutics shares does Gregory B. Brown own after this Form 4 filing for LSTA?

After the reported grant, Gregory B. Brown beneficially owns 95,659 shares of Lisata Therapeutics common stock, including 30,456 unvested restricted stock units.

What type of security did Gregory B. Brown receive in this Lisata (LSTA) Form 4?

Gregory B. Brown received restricted stock units tied to Lisata Therapeutics common stock, granted under the company’s 2018 Equity Incentive Compensation Plan.

Was there a purchase price for the 30,456 Lisata restricted stock units reported on this Form 4?

The Form 4 shows a transaction price of $0 per share for the 30,456 restricted stock units, reflecting that this was an equity award rather than an open-market purchase.

Is Gregory B. Brown a director or officer of Lisata Therapeutics (LSTA)?

According to the Form 4, Gregory B. Brown is a director of Lisata Therapeutics and is not listed as an officer or 10% owner in this filing.